June 27, 2022

UKRAINE: October 2021 Metabiota Thread By Blue Canaries Who Was Suspended By Twitter. Paul Pelosi Jr. Developing Clean Energy That Can Replace Gasoline And Diesel As Transportation Fuel Sources.

1. Metabiota (thread) - produces bio agents under diplomatic cover at "secret" labs, then sells pandemic insurance and trackers to help countries get ahead of what they are putting out. Company part of Pentagon's DRTA Program as well as funded by Rosemont Seneca (Hunter Biden).
2. Metabiota partners with industry and governments worldwide to build resilience to epidemics and protect global health.
5. Bio warfare scientists using diplomatic cover test man-made viruses at Pentagon bio labs in 25 countries across the world. These US bio-laboratories are funded by the Defense Threat Reduction Agency (DTRA) under a $ 2.1 billion military program.
8. "The USA is gaining total control over biological research facilities, researchers facilities, researchers and stocks of deadly viruses in Ukraine... By a lucky chance, Metabiota, a subcontractor, is sharing the building with Black & Veatch in Kyiv." (Link is considered harmful).
9. "This will allow the USA to control epidemiological situation in the region, get access to every development in the sphere and manipulate population size while increasing American pharmaceutical corporations’ profit" (Article continued)
10. 2018 Kiev... Also a reminder of who was in charge of Ukraine for the Obama Admin... (Article continued)
16. INVESTORS: Rosemont Seneca (RSTP) an investment firm led by Hunter Biden – was a lead financial backer of Metabiota, a pandemic tracking and response firm that has partnered with Peter Daszak’s EcoHealth Alliance and the Wuhan Institute of Virology.
Move along, nothing suspicious here. 🙄 [/sarcasm] emphasis mine
The National Pulse
written by Natalie Winter
Monday June 28, 2021

Rosemont Seneca Technology Partners – an investment firm led by Hunter Biden – was a lead financial backer of Metabiota, a pandemic tracking and response firm that has partnered with Peter Daszak’s EcoHealth Alliance and the Wuhan Institute of Virology.

Rosemont Seneca Technology Partners (RSTP) was an offshoot of Rosemont Capital, an investment fund founded by Biden and John Kerry’s stepson in 2009, that counted Biden as a Managing Director.

Among the companies listed on archived versions of the firm’s portfolio is Metabiota, a San Francisco-based company that purports to detect, track, and analyze emerging infectious diseases, The National Pulse can reveal.

Financial reports reveal that RSTP led the company’s first round of funding, which amounted to $30 million. Former Managing Director and co-founder of RSTP Neil Callahan – a name that appears many times on Hunter Biden’s hard drive – also sits on Metabiota’s Board of Advisors.

Since 2014, Metabiota has been a partner of EcoHealth Alliance as part of the U.S. Agency for International Development’s (USAID) “PREDICT” project, which seeks to “predict and prevent global emerging disease threats.”

As part of this effort, researchers from Metabiota, EcoHealth Alliance, and the Wuhan Institute of Virology collaborated on a study relating to bat infectious diseases in China. “Sensitive and broadly reactive RT-PCR assays were performed at Wuhan Institute of Virology, Chinese Academy of Sciences,” the paper notes.

The proximity between Hunter Biden and COVID-19’s origins are almost too convenient.

Among the researchers listed on the aforementioned 2014 paper are “bat lady” Shi Zhengli, the Director of the Center for Emerging Infectious Diseases at the Chinese Communist Party’s Wuhan Lab. The disgraced Peter Daszak – recently recused from the Lancet COVID-19 commission due to several conflicts of interest as a “longtime collaborator” of the Wuhan Institute of Virology – is also listed as an author.

Daszak is also a figure central to the potential origins of COVID-19. His EcoHealth Alliance funneled taxpayer dollars from Anthony Fauci’s National Institute of Allergy and Infectious Diseases (NIAID) to collaborate on bat coronavirus research in Wuhan.

Researchers from EcoHealth Alliance and Metabiota have also collaborated on presentations on how to “live safely with bats” and studies linking emerging infectious disease outbreaks to wildlife trade facilities including “wet markets.”

“Wildlife trade can facilitate zoonotic disease transmission and represents a threat to human health and economies in Asia, highlighted by the 2003 SARS coronavirus outbreak, where a Chinese wildlife market facilitated pathogen transmission,” the 2016 paper notes.

Researchers from Metabiota have also been listed alongside EcoHealth Alliance personnel on a 2014 study on henipavirus spillover, 2014 study on Ebola monitoring, 2015 study focusing on herpes, and 2015 study on viral diversity.

Beyond the ties to EcoHealth Alliance, Metabiota has also been embroiled in controversy for “bungling” America’s response to Ebola.

“An American company that bills itself as a pioneer in tracking emerging epidemics made a series of costly mistakes during the 2014 Ebola outbreak that swept across West Africa — with employees feuding with fellow responders, contributing to misdiagnosed Ebola cases and repeatedly misreading the trajectory of the virus,” an Associated Press (AP) investigation into the company found.

The company reportedly made the “already chaotic situation worse,” prompting World Health Organization officials to criticize the company:
Emails obtained by AP and interviews with aid workers on the ground show that some of the company’s actions made an already chaotic situation worse.

WHO outbreak expert Dr. Eric Bertherat wrote to colleagues in a July 17, 2014, email about misdiagnoses and “total confusion” at the Sierra Leone government lab Metabiota shared with Tulane University in the city of Kenema. He said there was “no tracking of the samples” and “absolutely no control on what is being done.”

“This is a situation that WHO can no longer endorse,” he wrote.
In April 2021, Joe Biden’s USAID announced a new initiative spearheaded by EcoHealth Alliance to track emerging infectious diseases with pandemic potential. Also collaborating on the taxpayer-funded venture is Metabiota, whose researchers have been listed as authors on papers from June 2021 relating to coronavirus surveillance in Africa.
17. Pilot Growth Management is currently the #1 investor in Metabiota. Neil Callahan, is the co-founder, who was also the co-founder of Rosemont Seneca.
18. "Neil Callahan – a name that appears many times on Hunter Biden’s hard drive – also sits on Metabiota’s Board of Advisors."
19. They were literally investing in a biolab company which houses and tracks deadly pathogens, then creates tracking and global virus outlooks and the marketing a pandemic insurance to go along with it. Here's to Metabiota and their ingenious, evil scheme. Who does this?
20. Dr. Nathan Wolfe --- the guy from the Bat Study and numerous other studies. Oh yeah... and another familiar face appears - Ghislaine Maxwell I'm sure they just had dinner. 👍 (I will link thread to that photo at the end)
21. In 2017, Metabiota announced some partnerships and set itself up to become the innovator of pandemic insurance. Not many countries would understand that they needed it or did they?
22. "Munich Reinsurance Company, the largest global reinsurer... and In-Q-Tel, Inc. (IQT), the strategic investor that accelerates the development of technologies to support the U.S. intelligence community, have signed strategic agreements with Metabiota."
23. "Working in collaboration, Marsh, Munich Re and Metabiota developed PathogenRX... It uses triggers such as Metabiota’s new Pathogen Sentiment Index which the epidemic risk specialists launched recently.

Artemis.bm, Catastrophe bonds, insurance linked securities, reinsurance capital & investment, risk transfer intelligence.
written by Staff
May 21, 2018

Global broker and risk consultancy Marsh has launched PathogenRX, an insurance product designed to protect businesses against pandemic risks such as the outbreak of infectious diseases, that utilises a parametric trigger provided by epidemic risk modeling specialists Metabiota and capacity from reinsurance giant Munich Re.

The impact of infectious disease outbreaks and other pandemics can be significant for businesses, ranging from direct impacts to extensive business interruption, which makes a parametric triggered event definition and risk transfer solution, backed by global reinsurance capacity a valuable product for corporate risk managers.

Of course this also meets the mandate of the major reinsurers such as Munich Re, bringing their reinsurance risk capital direct to the corporate market through such arrangements, while also helping to narrow an evident gap in traditional re/insurance protection.

Marsh said the solution can help to minimise financial losses caused by the outbreak of pandemics, citing the PathogenRX product as the “world’s first integrated risk solution for measuring and protecting against economic impact of infectious disease outbreaks.”

The insurance product will be offered to U.S. based companies, but can also protect their global operations as well. An attractive prospect for corporate risk managers for whom the impacts of epidemics and pandemics could be significant.

“Pandemics and epidemics are not your average risk. They may occur over several months, are often not confined to a specific region, and their unpredictability means they can scale, grow, and become quite costly to a range of businesses from hotels and restaurants to schools and airlines,” explained Martin South, President of Marsh’s US and Canada Division.

Marsh highlights that disease outbreaks such as Zika, MERS, and SARS can cause a significant financial impact to businesses and even whole industries that depend on the free movement of people, without fear for safety or health.

Citing data from a study, Marsh noted that as many as 90% of Miami, Florida businesses in an area that was badly affected by the 2016 Zika virus outbreak suffered a revenue and profit loss of as much as 40%.

Historically, businesses have not been able to measure the potential economic loss from a pandemic or epidemic, or effectively protect their bottom lines using insurance. Something this new product will now help them to do.

Working in collaboration, Marsh, Munich Re and Metabiota developed PathogenRX, which they call a fully integrated pandemic risk solution.

It uses triggers such as Metabiota’s new Pathogen Sentiment Index, which the epidemic risk specialists launched recently, as reported at the time by our sister site Reinsurance News.

This Index offers insight and analytics into infectious disease outbreaks, helping businesses to model their potential financial exposure to an outbreak and protect against this risk using insurance policy underwritten by Munich Re.

These policies can be highly customised, so as to tailor coverage for specific expenses, geographies, types of disease, or portions of a calendar year, Marsh explained.

“Metabiota’s mission is to make the world more resilient to epidemics and to accomplish this means working with insurance industry leaders, like Marsh and Munich Re, to develop new offerings to minimize the economic repercussions that can result from infectious diseases,” Bill Rossi, CEO of Metabiota said. “Our Pathogen Sentiment Index combines our team’s in-depth scientific knowledge with a novel way to measure the potential impact to consumer travel and spending as a result of an outbreak and trigger the necessary resources to offset it.”

“With PathogenRX, we are pushing the boundaries of insurability. Businesses now can better prepare for the potential of an epidemic or pandemic with a highly customizable risk modelling and transfer solution,” added Gunther Kraut, Head of Epidemic Risk Solutions at Munich Re. “This joint effort is an important part in our continued strategic push for innovation. It will pave a new frontier for the insurance industry by helping businesses become more resolute to the evolving health threats facing the world.”

Christian Ryan, US Hospitality, Sports and Entertainment Leader at Marsh and based in Dallas, explained to Artemis that the use of parametric triggers will mean payouts can be determined much more quickly, while coverage can be tailored to the needs of the insured.

The global nature of the product means that international businesses, such as in the hospitality sector, can attain coverage that could provide rapid pay outs to help their finances when business interruption, or expense due to the outbreak of diseases occur.

The product is another good example of parametric triggers enabling gaps in insurance protection to be filled efficiently, while pay outs can be disbursed more rapidly as well.

The product will use the parametric factors for definition of an event, but unless a cedent has an identifiable financial loss from the event a payout wouldn’t be made, we understand.

Hence the Metabiota index is an element of the overall payout trigger, but vital for identifying when an event qualifies under the terms of the insurance arrangement.
24. I TOLD YOU SO... says Metabiota. You should of bought our pandemic insurance in 2018. The PERFECT set-up... for what's next. Reminder, they are housing and tracking deadly pathogens.  

Center for Global Development
written by Eleni Smitham and Amanda Glassman
August 25, 2021

Pandemic risk is largely underestimated and actions to prepare for outbreaks are grossly underinvested. The spread and severity of COVID-19 felt like a surprise to many policymakers – a clear case in point. But careful analyses are suggesting that future pandemic risks are significant.

Last month, CGD hosted an event on predicting the frequency and scale of future pandemics to discuss what’s to come after the COVID-19 pandemic and the critical task of preparing for future outbreak probabilities. We were joined by Ben Oppenheim and Nicole Stephenson, who are modeling future pandemic risk at Metabiota; Robert Agyarko and Cristina Stefan, who are examining risk with an eye to ensuring rapid outbreak response at African Risk Capacity; as well as Dean Jamison, who has long argued that pandemic risk is underappreciated.

Here are three key takeaways from the event:

1. The next pandemic could be much sooner and more severe than we think COVID-19 is broadly viewed as being a “once in a lifetime” or “once in a century” pandemic. Modeling work based on historical data shows that this is not necessarily the case.

Ben Oppenheim and Nicole Stephenson reminded us that COVID-19 is not the only pandemic of this decade; we’ve seen a drumbeat of epidemiological events. Their analysis, based on historical data on epidemic frequency and geographic distribution, shows that the frequency and severity of spillover infectious disease – directly from wildlife host to humans – is steadily increasing. Figure 1 illustrates this trend. (To the right of the red dashed line is a projection, and the dashed blue line shows the 95 percent prediction interval.) 

CLICK HERE to read the entire article...
25. "AI modelling driven by companies such as BlueDot and Metabiota anticipated the Coronavirus (COVID-19) in China before it caught the world by surprise in late 2019 by both scouting its impact and its spread." Of course they did.
26. Now, everyone wants to partner with Metabiota and their "expertise." Unbelievable.
NRGLabNewTechnology published NRGLab and New Technology. Paul Pelosi Jr. is a member of management team of Viscoil Group of Companies and NRGLab. Paul Pelosi Jr. is interested in developing clean energy that can replace gasoline and diesel as transportation fuel sources.

Commie deep state globalist Democrats shut down our US energy independence and made us DEPENDENT primarily on Russia oil imports. Then same deep state globalist assholes start war with Russia by way of Ukraine and then cut off buying oil from Russia to create inflationary crisis in America due to high gas and diesel prices. They deliberately caused our economic crisis. (emphasis mine)

No comments: